Ernexa Therapeutics Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-06-21

Reporting Person: Gurrola Sandra M (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-21	Restricted Stock Unit	$	A	35000	Acquired		Common Stock (35000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: The option vests and becomes exercisable in four equal installments on June 21 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Ms. Gurrola's Executive Employment Agreement, dated as of June 16, 2021 and effective as of June 21, 2021), subject to continued service through each vesting date.